Radiopharmaceutical developer Immunomedics has appointed Robert DeLuccia as CEO to take over duties previously handled by the company's founder, Dr. David Goldenberg. DeLuccia formerly served as marketing vice president at both Pfizer Laboratories and
Radiopharmaceutical developer Immunomedics has appointed Robert DeLuccia as CEO to take over duties previously handled by the company's founder, Dr. David Goldenberg. DeLuccia formerly served as marketing vice president at both Pfizer Laboratories and Winthrop Pharmaceuticals, as well as U.S. president of Sanofi Winthrop Pharmaceuticals.
DeLuccia will assume immediate management of the company, allowing Goldenberg to center his efforts on Immunomedics' cancer therapeutics research and other projects. DeLuccia's responsibilities will include developing strategies to best use the company's technology and personnel, according to the Morris Plains, NJ-based firm.
Immunomedics manufactures and distributes antibody-based cancer and infection imaging agents throughout the U.S. and Europe. Its products include CEA-Scan, for the detection of colorectal cancer, and LeukoScan, for the diagnosis of bone infection. LeukoScan is currently under review by the Food and Drug Administration.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.